A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

Bispecific antibody: a tool for diagnosis and treatment of disease

(2010) S. SONGSIVILAI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors

(2009) B. Sennino et al.   CANCER RESEARCH

Development trends for therapeutic antibody fragments

(2009) Aaron L Nelson et al.   NATURE BIOTECHNOLOGY

PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

(2009) Emmanuelle di Tomaso et al.   PLoS One

The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains

(2009) Annemarie Honegger et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma

(2008) J. J. Hiles et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY